ONCAlert | 2018 ASCO Annual Meeting

The Utility of a Vascular Disrupting Agent in Ovarian Cancer

Bradley J. Monk, MD, FACOG, FACS
Published Online: 9:25 PM, Sun March 29, 2015
Bradley J. Monk, MD, FACOG, FACS, Director, Division of Gynecologic Oncology, Vice Chair, Department of Obstetrics and Gynecology, University of Arizona Cancer Center-Phoenix, discusses a phase II trial presented at the 2015 SGO meeting. The trial evaluated bevacizumab in combination with the vascular disrupting agent fosbretabulin for the treatment of patients with recurrent ovarian, tubal, or peritoneal carcinoma.

<<< View more from SGO 2015



Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.